News | ESC | May 06, 2020

ESC Congress Goes Virtual Amid COVID-19 Concerns

ESC Congress Goes Virtual Amid COVID-19 Concerns. #ESC #ESCcongress

May 6, 2020 — The European Society of Cardiology (ESC), one of the world's largest cardiovascular conferences, is cancelling its in-person meeting and moving to a virtual meeting Aug. 29 through Sept 1, 2020, due to the COVID-19 (SARS-CoV-2) containment efforts.

The decision by the ESC follows an announcement from the Dutch government banning public gatherings until Sept. 1 to prevent the spread of coronavirus. The current pandemic has prompted the government of the Netherlands to ban all public gatherings before Sept 1, so the ESC Congress cannot take place in Amsterdam as planned.

The new theme of the virtual meeting is aptly named "Challenging Times, Infinite Possibilities." The ESC said it is creating a digital platform to disseminate the key cardiovascular science in an engaging format and will feature key opinion leaders from around the world. 

The virtual meeting will include a dedicated COVID-19 track showcasing first-hand experience of top experts across the globe.

ECS said late-breaking trial sessions will present highly anticipated clinical results. Novel research presented in abstracts covering all areas of cardiovascular science. Key opinion leaders will explain how this new research impacts practice. New ESC clinical practice guidelines will be introduced and discussed by those who wrote them in virtual sessions.

The ESC said it will keep its call for late-breaking science open until May 21.

Updates for the virtual meeting can be found at www.escardio.org/Congresses-&-Events/ESC-Congress.

 

Related Cardiology Conference Cancellations Due to COVID-19:

Cardiology Meetings Continue to be Cancelled or Go Virtual Due to COVID-19

EuroPCR Cancels Annual Meeting Due to COVID-19

SCCT Plans to Make 2020 Annual Meeting Virtual Due to COVID-19

ACC Cancels 2020 Conference Amid Coronavirus Concerns

Heart Rhythm Society Cancels 2020 Meeting Due to COVID-19

European Heart Rhythm Association Cancelled Due to Coronavirus

Related Content

COVID-19 Positive STEMI Patients Have Higher Mortality, First data presented at #TCT2020 on COVID heart attack patients.

Getty Images

News | Coronavirus (COVID-19) | October 14, 2020
October 14, 2020 – The first outcomes data from the...
Very ill COVID-19 patients have a high rate of in-hospital sudden cardiac arrest and a very low survival rate.

Very ill COVID-19 patients have a high rate of in-hospital sudden cardiac arrest and very low survival rates. Getty Images

Feature | Coronavirus (COVID-19) | October 02, 2020
October 2, 2020 — Even when a sudden cardiac arrest happens inside a top hospital, where a code blue team is readily

An ECMO procedure at Tufts Medical Center in Boston. The FDA cleared the use of ECMO support for COVID-19 patients in April 2020. A new review of patients treated with ECMO showed it had positive outcomes in the most severe COVID-19 patients. Photo by Dave Fornell

News | Coronavirus (COVID-19) | September 29, 2020
September 29, 2020 –  Extracorporeal mem...
hort-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients with COVID-19 (SARS-CoV-2) who are risk assessed prior to receiving the drug. That is the finding of research published today in EP Europace, a journal of the European Society of Cardiology (ESC). #COVID19 #SARSCoV2 #hydroxychloroquine
News | Coronavirus (COVID-19) | September 25, 2020
September 25, 2020 — Short-term hydroxychloroquine treatment is not associated with lethal heart rhythms in patients
SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

SARS-CoV-2 infection of cells shown in green, left. This is inhibited by a modified form of cholesterol called 25-hydroxycholesterol (25HC), as seen in the cells in the right image. 25HC activates an enzyme called ACAT, found inside cells in the endoplasmic reticulum. ACAT then depletes accessible cholesterol on the cell’s membrane. It is a normally occurring process that gets kicked into high gear during some viral infections. Image from UC San Diego Health Sciences.

News | Coronavirus (COVID-19) | September 24, 2020
September 24, 2020 — Analyzing anonymized patient medical records,...
COVID-19 Therapy Drug Azithromycin May Increase Risk for Cardiac Events

Getty Images

News | Coronavirus (COVID-19) | September 17, 2020
September 17, 2020 — Debates over whether hydroxychloroquine should be taken to help lessen the duration and impact o